Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih W
Ann Hematol. 2024; 103(9):3573-3583.
PMID: 39145781
PMC: 11358163.
DOI: 10.1007/s00277-024-05912-8.
Huang J, Zhang P, Shen F, Zheng X, Ding Q, Pan Y
Front Cardiovasc Med. 2024; 11:1369701.
PMID: 38984355
PMC: 11231400.
DOI: 10.3389/fcvm.2024.1369701.
Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H
Life (Basel). 2024; 14(4).
PMID: 38672793
PMC: 11051164.
DOI: 10.3390/life14040523.
Suo S, Fu R, Qin A, Shao Z, Bai J, Chen S
J Hematol. 2024; 13(1-2):12-22.
PMID: 38644985
PMC: 11027776.
DOI: 10.14740/jh1245.
Stein B, Martin K
Hematology Am Soc Hematol Educ Program. 2019; 2019(1):397-406.
PMID: 31808903
PMC: 6913438.
DOI: 10.1182/hematology.2019001318.
Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia.
Guo C, Li Z
Med Sci Monit. 2019; 25:9262-9271.
PMID: 31801935
PMC: 6911306.
DOI: 10.12659/MSM.918719.
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T
BMC Cancer. 2019; 19(1):184.
PMID: 30819138
PMC: 6393965.
DOI: 10.1186/s12885-019-5387-9.
Prefibrotic myelofibrosis: treatment algorithm 2018.
Finazzi G, Vannucchi A, Barbui T
Blood Cancer J. 2018; 8(11):104.
PMID: 30405096
PMC: 6221891.
DOI: 10.1038/s41408-018-0142-z.
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
De Stefano V, Finazzi G, Barbui T
Blood Cancer J. 2018; 8(7):65.
PMID: 29946112
PMC: 6018810.
DOI: 10.1038/s41408-018-0101-8.
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach O, Sellar R, Martinod K, Cherpokova D, McConkey M, Chappell R
Sci Transl Med. 2018; 10(436).
PMID: 29643232
PMC: 6442466.
DOI: 10.1126/scitranslmed.aan8292.
Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
Ball S, Thein K, Maiti A, Nugent K
J Thromb Thrombolysis. 2018; 45(4):516-528.
PMID: 29404876
DOI: 10.1007/s11239-018-1623-4.
SOHO State-of-the-Art Update and Next Questions: MPN.
Bose P, Gotlib J, Harrison C, Verstovsek S
Clin Lymphoma Myeloma Leuk. 2017; 18(1):1-12.
PMID: 29277359
PMC: 5915302.
DOI: 10.1016/j.clml.2017.11.008.
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Scotch A, Kosiorek H, Scherber R, Dueck A, Slot S, Zweegman S
Leuk Res. 2017; 63:34-40.
PMID: 29096334
PMC: 8148892.
DOI: 10.1016/j.leukres.2017.10.002.
Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep. 2017; 12(5):389-396.
PMID: 28948496
DOI: 10.1007/s11899-017-0400-3.
The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D, Falchi L, Verstovsek S
Ann Hematol. 2017; 96(10):1595-1604.
PMID: 28808761
PMC: 5693670.
DOI: 10.1007/s00277-017-3099-2.
Persistent neutrophilia is a marker for an increased risk of venous thrombosis.
Kushnir M, Cohen H, Billett H
J Thromb Thrombolysis. 2016; 42(4):545-51.
PMID: 27383828
DOI: 10.1007/s11239-016-1398-4.
Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini A
Diagn Pathol. 2015; 10:29.
PMID: 25885405
PMC: 4407780.
DOI: 10.1186/s13000-015-0269-1.
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi A, Rodeghiero F
Leukemia. 2013; 27(9):1874-81.
PMID: 23739289
PMC: 3768558.
DOI: 10.1038/leu.2013.163.
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
Tefferi A, Barbui T
Leukemia. 2013; 27(8):1617-20.
PMID: 23558521
PMC: 3740400.
DOI: 10.1038/leu.2013.99.
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H
Blood. 2013; 121(10):1720-8.
PMID: 23315161
PMC: 3591796.
DOI: 10.1182/blood-2012-07-443770.